scholarly journals Pathogenesis, Diagnosis, and Management of Primary Antibody Deficiencies and Infections

2009 ◽  
Vol 22 (3) ◽  
pp. 396-414 ◽  
Author(s):  
Ari J. Fried ◽  
Francisco A. Bonilla

SUMMARY Primary antibody deficiencies are the most common primary immunodeficiency diseases. They are a heterogeneous group of disorders with various degrees of dysfunctional antibody production resulting from a disruption of B-cell differentiation at different stages. While there has been tremendous recent progress in the understanding of some of these disorders, the etiology remains unknown for the majority of patients. As there is a large spectrum of underlying defects, the age at presentation varies widely, and the clinical manifestations range from an almost complete absence of B cells and serum immunoglobulins to selectively impaired antibody responses to specific antigens with normal total serum immunoglobulin concentrations. However, all of these disorders share an increased susceptibility to infections, affecting predominantly the respiratory tract. A delay of appropriate treatment for some diseases can result in serious complications related to infections, while timely diagnosis and adequate therapy can significantly decrease morbidity and increase life expectancy and quality of life.

2019 ◽  
Vol 20 (8) ◽  
pp. 1898 ◽  
Author(s):  
Alessandra Bettiol ◽  
Giuseppe Lopalco ◽  
Giacomo Emmi ◽  
Luca Cantarini ◽  
Maria Letizia Urban ◽  
...  

Autoinflammatory diseases (AIDs) are heterogeneous disorders characterized by dysregulation in the inflammasome, a large intracellular multiprotein platform, leading to overproduction of interleukin-1(IL-1)β that plays a predominant pathogenic role in such diseases. Appropriate treatment is crucial, also considering that AIDs may persist into adulthood with negative consequences on patients’ quality of life. IL-1β blockade results in a sustained reduction of disease severity in most AIDs. A growing experience with the human IL-1 receptor antagonist, Anakinra (ANA), and the monoclonal anti IL-1β antibody, Canakinumab (CANA), has also been engendered, highlighting their efficacy upon protean clinical manifestations of AIDs. Safety and tolerability have been confirmed by several clinical trials and observational studies on both large and small cohorts of AID patients. The same treatment has been proposed in refractory Kawasaki disease, an acute inflammatory vasculitis occurring in children before 5 years, which has been postulated to be autoinflammatory for its phenotypical and immunological similarity with systemic juvenile idiopathic arthritis. Nevertheless, minor concerns about IL-1 antagonists have been raised regarding their employment in children, and the development of novel pharmacological formulations is aimed at minimizing side effects that may affect adherence to treatment. The present review summarizes current findings on the efficacy, safety, and tolerability of ANA and CANA for treatment of AIDs and Kawasaki vasculitis with a specific focus on the pediatric setting.


2020 ◽  
Vol 145 (2) ◽  
pp. AB217
Author(s):  
Junghee Shin ◽  
Daniel Liauw ◽  
Sabrina Siddiqui ◽  
Eun Jae Chung ◽  
Christina Price ◽  
...  

2004 ◽  
Vol 114 (4) ◽  
pp. 936-942 ◽  
Author(s):  
Ann Gardulf ◽  
Uwe Nicolay ◽  
Oscar Asensio ◽  
Ewa Bernatowska ◽  
Andreas Böck ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document